← All trials
NCT06674265
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Nov 30, 2026
- Completion date
- Nov 30, 2026
- First posted
- Nov 5, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kian Immune Cell CompanyLead sponsor
- Kian Immune Cell CompanySponsor investigator
- Iran University of Medical SciencesCollaborator
- Royan InstituteCollaborator
- Royan InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.